Attached files
file | filename |
---|---|
EX-99.1 - GENTA INC DE/ | v181630_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): April 20,
2010
|
||
GENTA
INCORPORATED
|
||
(Exact
Name of Registrant
as
Specified in Its Charter)
|
||
Delaware
|
||
(State
or Other Jurisdiction of Incorporation)
|
||
0-19635
|
33-0326866
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
200
Connell Drive
Berkeley
Heights, NJ
|
07922
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
|
(908)
286-9800
|
||
(Registrant’s
Telephone Number, Including Area Code)
|
||
(Former
Name or Former Address, if Changed Since Last Report)
|
||
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the Registrant
under any
of the following provisions:
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
o Pre -commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
-2(b))
o Pre -commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01 Other Events.
On April
20, 2010, Genta Incorporated, (the Company), announced the presentation of
initial results from the first human use of a gallium-containing compound to
treat serious infection. In a patient with cystic fibrosis and a
highly resistant lung infection, who has been treated over a 2-year period, high
concentrations of gallium were achieved in sputum. Moreover, sputum
concentrations were higher than simultaneous concentrations in blood and
continued to rise even after treatment had been stopped. Measured
concentrations in sputum equaled or exceeded concentrations that have been
reported lethal to bacteria in laboratory tests. The data were
presented at the annual meeting of the American Association of Cancer Research
in Washington, D.C.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
Number
|
Description
|
||
99.1
|
Press
Release of the Company dated April 20,
2010
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
GENTA
INCORPORATED
|
|||||
Date:
|
April
20, 2010
|
|
By:
|
/s/
GARY SIEGEL
|
|
Name: Gary Siegel | |||||
Title: Vice President, Finance | |||||